Evidence map›Paper›PMID 30349588›Full record

ArticleEuropean endocrinology2018

Sulfonylureas at the Glomerular Battlefield.

Sanjay Kalra, Deepak Khandelwal, Sarita Bajaj, Ashok Kumar Das

Open access · diamondAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in European endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sanjay KalraDepartment of Endocrinology, Bharti Hospital, Karnal, Haryana, India.
Deepak KhandelwalDepartment of Endocrinology, Maharaja Agrasen Hospital, Punjabi Bagh, New Delhi, India.
Sarita BajajDepartment of Medicine, Moti Lal Nehru Medical College, Allahabad, Uttar Pradesh, India.
Ashok Kumar DasDepartment of General Medicine, Pondicherry Institute of Medical Sciences, Puducherry, India.
Bharti Hospital · INMotilal Nehru Medical College · INPondicherry Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The kidney is important in the context of diabetes not only because it is involved in normal glucose homeostasis, but also because it is one of the most important end organs to be involved in diabetes complications. Glomeruli are the meeting point of both microvascular, or renal; and macrovascular, or cardiovascular, health in diabetes. Sulfonylureas are effective glucose-lowering drugs. While a sulfonylurea-based glucose-lowering strategy is nephro-safe and nephro-protective, this aspect of sulfonylurea pharmaco-biology has not been highlighted earlier. In this editorial, we discuss current preclinical and clinical trial evidence regarding the performance of modern sulfonylureas at the glomerular battlefield.

Indexed as

gliclazideglimepirideglomeruluskidneySulfonylurea

Identifiers

PMID30349588
PMCPMC6182921
OpenAlexW2891032169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.